Singapore Institute of Advanced Medicine Holdings

What Singapore Institute of Advanced Medicine Holdings does

Singapore Institute of Advanced Medicine Holdings (SAM) is an integrated advanced-medicine center headquartered at Singapore's Biopolis biomedical research hub, operating subsidiaries including Proton Therapy PTE LTD, Advanced Medicine Imaging, and Asia Healthpartners. SAM introduced proton beam therapy to Singapore in June 2023, making it one of the first providers of pencil-beam-scanning proton therapy in Southeast Asia, and runs the country's first GMP-compliant cyclotron and radiochemistry laboratory, which together enable on-demand production of radiopharmaceuticals including N-13 ammonia and Ac-225 PSMA for theranostics.

The service portfolio spans advanced radiotherapy (SBRT, IMRT, SRS and proton therapy), a full diagnostic-imaging suite (Digital PET/CT with digital photon counting, Ingenia 3.0T MRI with True Digital Architecture, Spectral CT, ultrasound with PureWave and shear-wave elastography, digital X-ray, and spectral digital mammography), nuclear medicine (bone scans, PET), and targeted radionuclide therapies (Lu-177 PSMA, Radium-223/Xofigo). A non-oncology service line, Low-Dose Radiotherapy for osteoarthritis and benign conditions, is offered on a self-pay basis at SGD 2,000–4,000 per 5–6 session course. Multi-disciplinary care is delivered through a team of radiation oncologists, radiologists, nuclear medicine specialists, and family physicians.

The business model is fee-for-service medical care, distributed through direct clinic visits at Biopolis and a satellite at Lucky Plaza/Orchard Road under the Asia Healthpartners brand, and through dedicated international patient packages targeting medical travelers from Indonesia, Malaysia, the Philippines, and Vietnam. Strategic partners include Australia's EnGeneIC Pty Limited (co-development of Proton Boron Capture Therapy and serving as SAM's international clinical trial site), China Life Insurance Singapore (cancer awareness MOU), and Biocina (CDMO for EnGeneIC's EDV nanocell manufacturing). The company is publicly listed on the Singapore Exchange (SGX).

Name

Singapore Institute of Advanced Medicine Holdings

Legal name

Singapore Institute of Advanced Medicine Holdings Ltd.

Website

https://advancedmedicine.sg

Company type

Public

Founded year

2011

Operating status

Operating

Short description

Singapore Institute of Advanced Medicine Holdings is an SGX-listed, Singapore-based advanced medical center providing proton beam therapy, advanced radiotherapy, full-body diagnostic imaging, nuclear medicine, and theranostics to oncology patients across Singapore and Southeast Asia.

Ownership category

akta.pro rank

Product category

Radiation Oncology Services

NAICS

Diagnostic Imaging Centers (621512), Specialty (except Psychiatric and Substance Abuse) Hospitals (6223), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Scientific Research and Development Services (5417)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000), Services-Medical Laboratories (8071)

akta.pro primary industry

Advanced Imaging & Specialty Radiology Centers (PET/CT, Nuclear Medicine, Interventional Radiology) (HLAFAKAB)

akta.pro secondary industries

Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Nuclear Medicine & Molecular Imaging (SPECT/PET) (HLAHABAE), Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE), Radiation Oncology (HLAKAFAC)

Keywords

• Proton beam therapy
• Radiation oncology services
• Diagnostic imaging
• Nuclear medicine theranostics
• Radiopharmaceutical production

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Services Revenue: SAM generates revenue through the provision of advanced medical services including proton beam therapy, radiotherapy, diagnostic imaging (MRI, CT, PET-CT, digital X-ray, mammography, ultrasound), nuclear medicine, and theranostics. Services are provided directly to patients on a fee-for-service basis, with pricing varying by treatment type and modality.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Singapore Institute of Advanced Medicine Holdings (SAM) operates an integrated advanced medical center at Biopolis, Singapore, delivering proton beam therapy, conventional radiotherapy, diagnostic imaging, and nuclear medicine/theranostics services. The center combines proton therapy introduced to Singapore in June 2023 with a full diagnostic imaging suite (MRI, CT, PET-CT, ultrasound, mammography, X-ray) and on-demand radiopharmaceutical production for cancer diagnosis and treatment.

Product overview

Singapore Institute of Advanced Medicine Holdings operates as an integrated medical center offering a comprehensive portfolio of cancer diagnostic and treatment services. The core offering includes Proton Therapy SG (proton beam therapy for cancer treatment, available since June 2023), Advanced Medicine Imaging (MRI, CT, X-ray, ultrasound, mammography), and Nuclear Medicine & Theranostics (PET/CT, radiopharmaceuticals, Lu-177 PSMA and Radium-223 therapies). The center provides both proton and conventional radiotherapy including SBRT, IMRT, and SRS. A distinctive capability is the on-demand production of radiopharmaceuticals including N-13 ammonia and Ac-225 PSMA. The institution also offers emerging treatments such as Low-Dose Radiotherapy for arthritis and participates in research on Proton Boron Capture Therapy.

Differentiator

Problem solved

Functional benefit

Products and services

• Proton Therapy SG Proton beam therapy using positively charged particles to precisely target and destroy cancer cells with minimal exit dose in normal organs. Available at SAM's Biopolis Proton Therapy clinic in Singapore since June 2023.
• Radiotherapy (SBRT, IMRT, SRS) Advanced X-ray-based radiotherapy techniques including Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT), and Stereotactic Radiosurgery (SRS) for precise tumor targeting. Offered alongside proton therapy for cancer patients.
• Digital PET/CT Digital photon counting PET/CT scanner providing approximately 2x sensitivity, resolution, and quantitative gains compared to analog systems. Enables faster scan times and detection of smaller lesions for cancer staging and diagnosis.
• Ingenia 3.0T MRI True Digital MRI system that digitizes MR signals directly in the RF coil, delivering up to 40% higher signal-to-noise ratio and reducing 50% of scan time to 8 minutes or less per sequence.
• Spectral CT Detector-based CT enabling simultaneous acquisition of anatomical data and tissue composition with iDose technology for lower radiation and better image quality, plus MicroCPA for fast-moving organs.
• Ultrasound Advanced ultrasound system with PureWave crystal technology providing up to 76% improved penetration, 213% increase in temporal resolution, and shear wave elastography capability.
• Digital X-Ray Digital X-ray system with automatic exposure control (AEC) for short, accurate exposures with effective dose management and multi-resolution image processing software.
• Digital Mammography Spectral mammography system with photon-counting technology delivering 11% image quality improvement, 50um pixel size, and Smart AEC that adjusts radiation based on breast density while eliminating 95% of scattered radiation.
• Lu-177 PSMA Therapy Targeted radionuclide treatment for advanced prostate cancer that binds to prostate-specific membrane antigen (PSMA) with radioactive nuclides to selectively target and neutralize cancer cells.
• Radium-223 (Xofigo) Therapy Alpha radiation therapy for castrate-resistant prostate cancer that has spread to the bones, targeting areas of high bone turnover to provide overall survival benefit.
• Radiopharmaceuticals Radiopharmaceutical products including N-13 ammonia and Ac-225 PSMA for diagnostic and therapeutic applications in nuclear medicine, produced on-demand in SAM's in-house generators and radiopharmaceutical laboratory.
• Nuclear Medicine & Theranostics Nuclear medicine services including bone scans and PET scans, with on-demand radiopharmaceutical production from in-house generators enabling same-day results, plus targeted radionuclide therapies.
• Low-Dose Radiotherapy (LDRT) Ultra low-dose radiotherapy for inflammatory joint diseases including osteoarthritis and tendinitis, providing pain relief and reduced inflammation without cancer therapy side effects. Course of 5-6 sessions over 2-3 weeks costs $2,000-$4,000 SGD out-of-pocket.
• Advanced Medicine Imaging Comprehensive diagnostic center offering ultrasound, X-ray imaging, computed tomography (CT), and 3T magnetic resonance imaging (MRI) services at the Biopolis campus.
• GP & Wellness General practitioner and wellness services providing primary healthcare and health screening services at the Biopolis clinic.

Quantifiable outcome

• Over 300 patients in Singapore have received proton beam therapy for cancer treatment
• +7 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• China Life Insurance (Singapore)coreStrategic or Co-development Partner · 29 May 2025A Memorandum of Understanding (MOU) was signed between China Life Insurance (Singapore) and SAM Holdings on 29 May 2025. The partnership aims to promote cancer awareness and enhance access to medical knowledge across international communities. As part of this initiative, SAM hosted a delegation from Chongqing Yongchuan District in October 2025, sharing insights on the EnGeneIC Dream Vector (EDV) technology and advancements in cancer treatment.
• EnGeneIC Clinical Trial SitessupportingStrategic or Co-development Partner · 13 May 2025EnGeneIC launched a groundbreaking new Australian trial for innovative cancer therapy, with an international trial site in Singapore to follow through the SAM partnership. SAM serves as the international clinical trial site partner for EnGeneIC's EDV nanocell clinical development program.
• BiocinasupportingImplementation/ SI/ Consulting Partner · 24 September 2024EnGeneIC partnered with global CDMO (Contract Development and Manufacturing Organization) Biocina to advance their pioneering cancer treatment. SAM's partnership with EnGeneIC extends access to these manufacturing capabilities for clinical development of EDV nanocell-based cancer therapies.
• EnGeneIC Pty LimitedcoreStrategic or Co-development Partner · 10 June 2024Singapore Institute of Advanced Medicine Holdings entered into a strategic partnership with EnGeneIC Pty Limited, an Australia-based clinical-stage biopharmaceutical company. The partnership focuses on biopharmaceutical innovations in cancer treatment, including the development of Proton Boron Capture Therapy (PBCT) using EnGeneIC's Dream Vector (EDV) nanocell technology for targeted drug delivery. The collaboration was formalized in June 2024 and includes a published research paper on microdosimetry and treatment planning for PBCT.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• National Cancer Centre Singapore (NCCS): Singapore's flagship public-sector cancer center offering radiotherapy and nuclear medicine; directly competes with SAM for Singapore oncology patients and was the prior employer of one of SAM's radiation oncologists.
• Icon Cancer Centre: Asia-Pacific radiation oncology provider with Singapore presence offering radiotherapy, including emerging advanced modalities; directly competes with SAM in the Singapore oncology market.

Broad incumbents

• Mount Elizabeth Hospital (IHH Healthcare): Large Singapore private tertiary hospital offering oncology, radiotherapy, and diagnostic imaging; competes with SAM for private oncology patients and medical tourism, though as part of a much broader hospital portfolio.
• Raffles Hospital: Singapore private hospital group providing oncology, radiotherapy, and advanced imaging services under the Raffles Medical Group brand; competes with SAM for private-pay and international patients.
• Gleneagles Hospital Singapore: Tertiary private hospital in Singapore with established oncology and diagnostic imaging departments; competes with SAM for both domestic and regional medical-tourism patients.
• IBA (Ion Beam Applications): Global proton therapy equipment vendor and operator of proton therapy centers; comparable as a technology and proton-therapy-services counterpart, though far larger and equipment-supply oriented.

Regional players

• Bumrungrad International Hospital: Leading Bangkok-based medical-tourism hospital with comprehensive oncology and advanced imaging services; competes with SAM for ASEAN patients seeking cross-border cancer treatment, though based in Thailand rather than Singapore.
• Subang Jaya Medical Centre (Ramsay Sime Darby): Malaysian private tertiary hospital offering oncology and diagnostic imaging; serves a similar Southeast Asian patient base but anchored in Malaysia rather than Singapore.

Others

• Varian Medical Systems (Siemens Healthineers): Supplier of the Varian ProBeam proton therapy system that SAM operates; comparable as the leading radiation oncology and proton therapy technology vendor underpinning SAM's clinical platform.
• EnGeneIC: Australia-based clinical-stage biopharmaceutical partner of SAM, developing EDV nanocell and Proton Boron Capture Therapy; comparable as a strategic biopharma collaborator tied to SAM's oncology research pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@AdvancedMedicine2024
• Facebookfacebook.com/AdvancedMedicineHoldings
• Instagraminstagram.com/protontherapysg
• LinkedInlinkedin.com/company/singapore-institute-of-advanced-medicine

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Singapore Institute of Advanced Medicine Holdings